Q3 Earnings Estimate for TYRA Issued By HC Wainwright

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Equities research analysts at HC Wainwright issued their Q3 2027 earnings per share estimates for shares of Tyra Biosciences in a report issued on Thursday, May 14th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($0.78) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.63) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2027 earnings at ($0.80) EPS.

A number of other analysts have also issued reports on TYRA. Wedbush boosted their price target on Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Wall Street Zen lowered Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Barclays started coverage on Tyra Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating on the stock. William Blair started coverage on Tyra Biosciences in a research note on Tuesday, February 10th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group began coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They issued a “buy” rating and a $50.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $46.50.

Tyra Biosciences Stock Down 5.3%

TYRA stock opened at $33.78 on Monday. Tyra Biosciences has a twelve month low of $8.75 and a twelve month high of $40.65. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -15.50 and a beta of 0.79. The business’s fifty day simple moving average is $36.17 and its two-hundred day simple moving average is $29.36.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04).

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently bought and sold shares of TYRA. Hilton Head Capital Partners LLC acquired a new position in Tyra Biosciences in the 1st quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $51,000. Chung Wu Investment Group LLC acquired a new position in shares of Tyra Biosciences during the 4th quarter worth approximately $53,000. Federated Hermes Inc. raised its stake in shares of Tyra Biosciences by 586.3% during the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after buying an additional 1,841 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of Tyra Biosciences stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. The trade was a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.50% of the stock is currently owned by company insiders.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.